Influence of thyroid hormone receptors on breast cancer cell proliferation

Conde, Isabel; Paniagua, Ricardo; Zamora, Javier; Blánquez, M. J.; Fraile, Benito; Ruiz, Andrés García; Arenas, María Isabel

doi:10.1093/annonc/mdj040

Cited by 70 publications

(72 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies described TR␣ as located in the nuclei of epithelial cells from normal breast ducts and acini, whereas in breast cancer cells such receptors are located in the cytoplasm (8). Moreover, TR␤ presented a nuclear location in benign proliferative diseases and carcinomas in situ and a cytoplasmic location in normal breast and infiltrative carcinomas (8).…”

Section: Discussionmentioning

confidence: 96%

“…No difference was evident in the localization of THRs in BDL cholangiocytes after T3 administration. The change in cell localization of THRs in normal mammary epithelial cells with respect to pathological conditions has been described (8). Previous studies described TR␣ as located in the nuclei of epithelial cells from normal breast ducts and acini, whereas in breast cancer cells such receptors are located in the cytoplasm (8).…”

Section: Discussionmentioning

confidence: 99%

“…Many mutations of THRs and methylations in the promoter of this receptor have been described in different carcinoma types (38). Thus it is possible that variations of the expression or cellular location of THRs, which may cause changes in its functionality, could increase the tumoral development or promote an advantage in the cellular transformation (8). However, because no data on the expression of THRs in malignant cholangiocytes are available, further studies comparing the expression of THRs both in benign and malignant biliary diseases are required to establish the degree of involvement of these receptors in the development of biliary diseases.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2

Fava¹,

Ueno²,

Glaser³

et al. 2007

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

.-The role of the thyroid hormone agonist 3,3Ј,5 L-tri-iodothyronine (T3) on cholangiocytes is unknown. We evaluated the in vivo and in vitro effects of T3 on cholangiocyte proliferation of bile duct-ligated (BDL) rats. We assessed the expression of ␣ 1-, ␣2-, ␤1-, and ␤2-thyroid hormone receptors (THRs) by immunohistochemistry in liver sections from normal and BDL rats. BDL rats were treated with T3 (38.4 g/day) or vehicle for 1 wk. We evaluated 1) biliary mass and apoptosis in liver sections and 2) proliferation in cholangiocytes. Serum-free T3 levels were measured by chemiluminescence. Purified BDL cholangiocytes were treated with 0.2% BSA or T3 (1 M) in the absence/presence of U-73122 (PLC inhibitor) or BAPTA/AM (intracellular Ca 2ϩ chelator) before measurement of PCNA protein expression by immunoblots. The in vitro effects of T3 (1 M) on 1) cAMP, IP3, and Ca 2ϩ levels and 2) the phosphorylation of Src Tyr139 and Tyr530 (that, together, regulate Src activity) and ERK1/2 of BDL cholangiocytes were also evaluated. ␣ 1-, ␣2-, ␤1-, and ␤2-THRs were expressed by bile ducts of normal and BDL rats. In vivo, T3 decreased cholangiocyte proliferation of BDL rats. In vitro, T3 inhibition of PCNA protein expression was blocked by U-73122 and BAPTA/AM. Furthermore, T3 1) increased IP3 and Ca 2ϩ levels and 2) decreased Src and ERK1/2 phosphorylation of BDL cholangiocytes. T3 inhibits cholangiocyte proliferation of BDL rats by PLC/IP3/Ca 2ϩ -dependent decreased phosphorylation of Src/ERK1/2. Activation of the intracellular signals triggered by T3 may modulate the excess of cholangiocyte proliferation in liver diseases.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2

Fava¹,

Ueno²,

Glaser³

et al. 2007

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

show abstract

“…Experimental studies have shown that THs influence both the differentiation of normal breast cells [44] and the proliferation of BC cells [44,50,51] . The proliferative effect of T3 has been demonstrated in various types of cancer.…”

Section: Cancermentioning

confidence: 99%

Triiodothyronine and breast cancer

Síbio¹,

Oliveira²,

Moretto³

et al. 2014

WJCO

View full text Add to dashboard Cite

The thyroid hormones (THs), triiodothyronine (T3) and thyroxine (T4), are essential for survival; they are involved in the processes of development, growth, and metabolism. In addition to hyperthyroidism or hypothyroidism, THs are involved in other diseases. The role of THs in the development and differentiation of mammary epithelium is well established; however, their specific role in the pathogenesis of breast cancer (BC) is controversial. Steroid hormones affect many human cancers and the abnormal responsiveness of the mammary epithelial cells to estradiol (E2) in particular is known to be an important cause for the development and progression of BC. The proliferative effect of T3 has been demonstrated in various types of cancer. In BC cell lines, T3 may foster the conditions for tumor proliferation and increase the effect of cell proliferation by E2; thus, T3 may play a role in the development and progression of BC. Studies show that T3 has effects similar to E2 in BC cell lines. Despite controversy regarding the relationship between thyroid disturbances and the incidence of BC, studies show that thyroid status may influence the development of tumor, proliferation and metastasis.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Thyroid hormone; Triiodothyronine; Breast cancer; Mammary gland and metabolism Core tip: Breast cancer (BC) is a malignant tumor occurring much more frequently in women than in men; worldwide, the incidence of BC has increased markedly in recent years. It is estimated that 1.7 million women will be diagnosed with BC in 2020, marking an increase of 26%, compared to the current incidence: 1.35 million new cases annually. Countless environmental risk factors, pathological conditions, and physiological agents, as well as thyroid hormones (THs), have been involved in the development of BC. Various lines of evidence suggest tumor-promoting effects of THs. The literature contains controversial reports regarding the relationship between thyroid diseases and BC; furthermore, studies reporting both an excess of and a lack of THs may affect breast development and progression to cancer. Epidemiologically, many studies suggest that hyperthyroidism is a factor in the development of BC. Furthermore, experimental studies have shown that high levels of THs reduce the interval of multiplication of BC cell lines. Therefore, the influence of THs on BC is unclear. However, the majority of BC research suggests a relationship, primarily, when the molecular aspects of these hormones are considered in the progression of this type of tumor.De Sibio MT, de Oliveira M, Moretto FCF, Olimpio RMC, Conde SJ, Luvizon AC, Nogueira CR. Triiodothyronine and breast TOPIC HIGHLIGHT Triiodothyronine and breast cancer INTRODUCTIONThyroid hormones (THs), 3,5,3′,-triiodothyronine (T3) and thyroxine (T4), play critical roles in the differentiation, growth, metabolism, and physiological function of nearly all mammalian tissues [1,2] ; in addition, they are required for amphibian metamorphosis [3] ....

show abstract

“…Thyroid hormone receptors affect both the normal breast cell differentiation and breast cancer cell proliferation, with effects of thyroid hormones similar to those caused by estrogens. 2,3 Some studies have indicated thyroid autoimmune changes as prognostic factors in breast cancer. 4 Relationship between thyroid diseases with breast cancer was demonstrated in several studies.…”

Section: Introductionmentioning

confidence: 99%

TSH receptor antibodies in breast cancer and benign breast disease: a hospital based study

Krishnaswamy

Sattar

2017

Int Surg J

View full text Add to dashboard Cite

Background: Associations between breast cancer, benign breast tumours and thyroid disorders are reported in numerous studies. Relationship between thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb), and breast cancer have been previously demonstrated. However, no analysis has been performed concerning an association between thyrotropin (TSH) receptor antibodies (TSHRAb) and breast cancer. The aim of the study was to evaluate the presence of TSH Receptor antibodies in women with breast cancer or benign breast tumours, and to analyze a possible relationship between TSH Receptor antibodies, and these two groups of breast diseases with emphasis to laboratory findings. Methods: Clinical and laboratory details of 87 women hospitalized were prospectively analyzed, using an Post hoc Tukey HSD for normally distributed continuous data, chi-square test for comparison. Results: TSH Receptor antibody levels in breast cancer was statistically significant. We observed TSHRAb more frequently in patients with breast cancer. We found that TSHRAb is the only variable possessing as a prognostic marker for breast cancer. Conclusions: The present study indicates that the serum levels of TSH Receptor Antibody are significant higher in patients with Breast cancer. These results have implications not only for the screening of patients but also for the development of new prognostic markers. Further high-quality prospective studies are needed to explore whether TSH Receptor Antibodies are potential prognostic markers for patients with Breast cancer.

show abstract

Influence of thyroid hormone receptors on breast cancer cell proliferation

Abstract: The results of this study reveal substantial changes in the expression profile of thyroid hormone receptors suggesting a possible deregulation that could trigger breast cancer development.

Cited by 70 publications

References 18 publications

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2

Triiodothyronine and breast cancer

TSH receptor antibodies in breast cancer and benign breast disease: a hospital based study

Contact Info

Product

Resources

About

Influence of thyroid hormone receptors on breast cancer cell proliferation

Abstract: The results of this study reveal substantial changes in the expression profile of thyroid hormone receptors suggesting a possible deregulation that could trigger breast cancer development.

Cited by 70 publications

References 18 publications

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP3/Ca2+-dependent downregulation of SRC/ERK1/2

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP3/Ca2+-dependent downregulation of SRC/ERK1/2

Triiodothyronine and breast cancer

TSH receptor antibodies in breast cancer and benign breast disease: a hospital based study

Contact Info

Product

Resources

About

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2

Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP₃/Ca²⁺-dependent downregulation of SRC/ERK1/2